



PATENT
ATTORNEY DOCKET NO. 07540/020003

1647
235
[Signature]

Certificate of Mailing: Date of Deposit: <u>December 20, 2002</u>	
I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.	
<u>Julie A. Brown</u> Printed name of person mailing correspondence	<u>Julie A. Brown</u> Signature of person mailing correspondence

TECH CENTER 1600/2900

JAN 02 2003

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	M.A. Walter, <i>et al.</i>	Art Unit:	1647
Serial No.:	09/292,862	Examiner:	Sharon L. Turner
Filed:	April 16, 1999	Customer No.:	21559
Title:	NOVEL MUTATIONS IN THE <i>FREAC3</i> GENE FOR DIAGNOSIS AND PROGNOSIS OF GLAUCOMA AND ANTERIOR SEGMENT DYSGENESIS		

Commissioner for Patents
Washington, D.C. 20231

REPLY TO RESTRICTION REQUIREMENT

In reply to the Examiner's Action mailed November 29, 2002, Applicants elect the invention of Group II claims, 18-22 and 27-32 to the extent of peptide therapy. Applicants also elect species (A), glaucoma. These elections are made without traverse.

Applicants also provide the following amendments and remarks.

AMENDMENT

Please amend claims 18 and 28-31 as follows.

18. (Amended) A method for treating a developmental defect or a disease of the eye, said method comprising increasing the FREAC3 biological activity in a mammal diagnosed as having developmental defect or a disease of the eye.

27. (Amended) The method of claim 22, wherein said number of biologically active FREAC3 molecules is increased by administering to said mammal a composition comprising a wild-type FREAC3 polypeptide and a pharmaceutically acceptable carrier.

28. (Amended) The method of claim 27, wherein said pharmaceutically acceptable carrier is physiological saline.

F² 29. (Amended) The method of claim 27, wherein said composition is delivered by ophthalmic administration.

30. (Amended) The method of claim 27, wherein said composition is delivered by intraorbital administration.

31. (Amended) The method of claim 27, wherein said wild-type FREAC3 polypeptide is substantially pure.

A "marked up" version of the claims showing the changes made and an appendix of the claims as pending are attached.

Applicants respectfully request that, effective immediately, all communication in this case be addressed to:


Kristina Bieker-Brady, Ph.D.
Clark & Elbing LLP
101 Federal Street
Boston, MA 02110

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date:

December 20, 2002



Kristina Bieker-Brady, Ph.D.
Reg. No. 39,109

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



21559
PATENT & TRADEMARK OFFICE

\\Clark-w2k1\documents\07540\07540.020003 Reply to RR of 11.29.02.wpd